NCT06753422

Brief Summary

This research work is a clinical trial that will assess the impact of kefir consumption on the gut microbiota profile and athletic performance of female soccer players of age 18-29 years. The participants were divided into two groups namely the kefir intervention group and the control group. The primary end points are the modifications in the alpha diversity of the gut microbiome and the beta diversity of the gut microbiome and also the athletic performance outcomes like VO2 max and finishing speed which will be measured using the 30-15 Intermittent Fitness Test. The other outcomes of the study are the changes in the body composition (measured through BIA and skinfold), the changes in the dietary intake and the variations in certain microbial genera such as Akkermansia muciniphila and Faecalibacterium prausnitzii. The study will be the first to evaluate whether kefir intake can increase the microbial diversity, increase the VO2max and improve the body composition of professional athletes. The anticipated outcomes of this study are enhanced gut microbial diversity, enhanced VO2max and finishing speed, and positive alteration in the body composition parameters.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
21

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2024

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 5, 2024

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

December 20, 2024

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 31, 2024

Completed
Last Updated

December 31, 2024

Status Verified

December 1, 2024

Enrollment Period

1 month

First QC Date

December 20, 2024

Last Update Submit

December 30, 2024

Conditions

Keywords

KefirGut microbiotaAthletic performanceFemale AthletesFunctional foodsBody compositionDietary intake

Outcome Measures

Primary Outcomes (2)

  • Gut Microbiota Composition Change

    Changes in gut microbiota diversity and abundance at genus and phylum levels, assessed through 16S rRNA gene sequencing of stool samples.

    At baseline and after 4 weeks of intervention (Week 5)

  • Athletic Performance Improvement

    Improvement in athletic performance as measured by the 30-15 Intermittent Fitness Test, evaluating VO2max and finishing speed.

    At baseline and after 4 weeks of intervention (Week 5)

Secondary Outcomes (6)

  • Dietary Intake Assessment

    At baseline and after 4 weeks of intervention (Week 5)

  • Body weight (kg)

    At baseline and after 4 weeks of intervention (Week 5)

  • Body Fat Percentage (%)

    At baseline and after 4 weeks of intervention (Week 5)

  • Fat mass (kg)

    At baseline and after 4 weeks of intervention (Week 5)

  • Fat-free mass (kg)

    At baseline and after 4 weeks of intervention (Week 5)

  • +1 more secondary outcomes

Study Arms (2)

Kefir Consumption Group

EXPERIMENTAL

Participants in this group will consume 200 ml of kefir daily for 4 weeks. Their diet will remain ad libitum, with no additional dietary restrictions or standardization applied during the intervention period. The primary intervention in our study is the daily consumption of kefir (200 ml/day). No additional drug or medical device was used during the intervention or data collection process. The study focused solely on kefir consumption and its effects on athletic performance and gut microbiota.

Dietary Supplement: Kefir

Control Group

NO INTERVENTION

Participants in this group will not receive any specific intervention. They will continue their usual diet ad libitum, with no dietary restrictions or standardization applied during the study period.

Interventions

KefirDIETARY_SUPPLEMENT

200 ml/day kefir The primary intervention in our study is the daily consumption of kefir (200 ml/day). No additional drug or medical device was used during the intervention or data collection process. The study focused solely on kefir consumption and its effects on athletic performance and gut microbiota.

Also known as: Altınkılıç Lactose-free Kefir, The kefir product used in this study was purchased independently with no sponsorship or involvement from the manufacturer
Kefir Consumption Group

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Professional female soccer player
  • Aged between 18 and 35 years
  • Regular participation in a structured training program
  • No allergy or intolerance to kefir or dairy products
  • Willingness to voluntarily participate in the study
  • Signed informed consent form

You may not qualify if:

  • History of allergy or intolerance to kefir or dairy products
  • Presence of chronic diseases (e.g., diabetes, heart disease, kidney failure)
  • Use of antibiotics or probiotic supplements within the last 3 months
  • Pregnancy or breastfeeding
  • Inability to comply with the study protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fatih Vatan Sports Club

Istanbul, Istanbul, 34091, Turkey (Türkiye)

Location

MeSH Terms

Interventions

Kefir

Intervention Hierarchy (Ancestors)

Fermented BeveragesBeveragesDiet, Food, and NutritionPhysiological PhenomenaCultured Milk ProductsMilkFermented FoodsDairy ProductsFoodFood and Beverages

Study Officials

  • Duygu Sağlam, Associate Professor

    Acibadem University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 20, 2024

First Posted

December 31, 2024

Study Start

May 1, 2024

Primary Completion

June 5, 2024

Study Completion

December 1, 2024

Last Updated

December 31, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will share

De-identified individual participant data from gut microbiota analysis, including genus and phylum-level diversity and abundance, assessed using 16S rRNA sequencing. De-identified performance test data, such as VO2max and finishing speed results from the 30-15 Intermittent Fitness Test. De-identified body composition data, including body fat percentage and lean muscle mass assessed using BIA and caliper measurements. De-identified dietary intake data collected through 3-day food records, including macronutrient and micronutrient consumption.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
De-identified IPD and supporting documents (e.g., Study Protocol, SAP) will be available starting 6 months after publication of primary results and will remain available indefinitely
Access Criteria
Researchers with a methodologically sound research proposal, approved by an independent ethics committee, will be able to access de-identified individual participant data (IPD) and supporting documents (e.g., Study Protocol, SAP). Data will be shared through a secure online repository upon request. Access will be granted after signing a Data Use Agreement, ensuring data confidentiality and ethical use.

Locations